Chardan Capital Maintains Buy Rating on ProQR Therapeutics, Raises PT to $4

Chardan Capital Maintains Buy Rating on ProQR Therapeutics, Raises PT to $4

Chardan Capital has maintained its Buy rating on ProQR Therapeutics (Nasdaq: PRQR) and raised its price target to $4, as reported on July 2, 2025. The analyst firm cited the company's significant progress in its RNA editing pipeline and strong financial position as the primary drivers behind the bullish outlook. ProQR reported its Q2 2025 financial and operational results, highlighting the submission of a Clinical Trial Application for AX-0810, its lead program targeting NTCP for cholestatic diseases, with initial Phase 1 data expected in Q4 2025 [1].

The company maintains a strong financial position with €119.8 million in cash, providing runway into mid-2027. ProQR also reported a net loss of €22.3 million for H1 2025, with notable developments including advancing AX-2402 for Rett Syndrome and achieving $2.0 million in milestone payments from its Eli Lilly collaboration [1]. Chardan's positive assessment reflects the company's clinical progress and robust financial position, with the potential for milestone payments from the Eli Lilly partnership serving as an additional catalyst.

The upcoming Analyst and Investor Event this fall is expected to provide detailed insights into the AX-0810 Phase 1 trial design and set expectations for the 2025 data readout, further fueling investor interest. ProQR's diversified pipeline, which includes programs targeting MASH (AX-2911) and cardiovascular disease (AX-1412), also contributes to the positive outlook. The company's Axiomer RNA editing platform has the potential to yield a new class of medicines for diverse types of diseases, positioning ProQR as a leader in transformative RNA therapies [1].

References:

[1] https://www.stocktitan.net/news/PRQR/pro-qr-announces-second-quarter-2025-operating-and-financial-3dney9j6qc9i.html